Citation: | ZENG Xi, LI Jing, KANG Le-ni, et al. Effectiveness of Different Testing Strategies Applied for Cervical Cancer Screening in Shuangliu District, Chengdu City[J]. Journal of Sichuan University (Medical Sciences), 2022, 53(5): 896-903. DOI: 10.12182/20220960502 |
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2021,71(3): 209–249. DOI: 10.3322/caac.21660
|
[2] |
BHATLA N, SINGHAL S. Primary HPV screening for cervical cancer. Best Pract Res Clin Obstet Gynaecol,2020,65: 98–108. DOI: 10.1016/j.bpobgyn.2020.02.008
|
[3] |
CHOI Y J, PARK J S. Clinical significance of human papillomavirus genotyping. J Gynecol Oncol, 2016, 27(2): e21[2021-11-20].https://doi.org/10.3802/jgo.2016.27.e21.
|
[4] |
SPENCE A R, GOGGIN P, FRANCO E L. Process of care failures in invasive cervical cancer: Systematic review and meta-analysis. Prev Med,2007,45(2/3): 93–106. DOI: 10.1016/j.ypmed.2007.06.007
|
[5] |
CHEN L, ZHANG Y, YOUNG R, et al. Effects of vaccine-related conspiracy theories on Chinese young adults’ perceptions of the HPV vaccine: An experimental study. Health Commun,2021,36(11): 1343–1353. DOI: 10.1080/10410236.2020.1751384
|
[6] |
SAWAYA G F, SMITH-MCCUNE K, KUPPERMANN M. Cervical cancer screening: More choices in 2019. JAMA,2019,321(20): 2018–2019. DOI: 10.1001/jama.2019.4595
|
[7] |
DERBIE A, MEKONNEN D, WOLDEAMANUEL Y, et al. HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): A systematic review. Infect Agent Cancer, 2020, 15: 9[2021-11-20]. https://doi.org/10.1186/s13027-019-0268-z.
|
[8] |
XUE P, GAO L L, YIN J, et al. A direct comparison of four high-risk human papillomavirus tests versus the cobas test: Detecting CIN2+ in low-resource settings. J Med Virol,2019,91(7): 1342–1350. DOI: 10.1002/jmv.25451
|
[9] |
LI Y, MA L, YANG C, et al. A study on service capacity of primary medical and health institutions for cervical cancer screening in urban and rural areas in China. Chin J Cancer Res,2019,31(5): 838–848. DOI: 10.21147/j.issn.1000-9604.2019.05.13
|
[10] |
ZHANG S K, JIA M M, ZHAO D M, et al. Evaluation of p16/Ki-67 dual staining in the detection of cervical precancer and cancer in China. Cancer Epidemiol,2019,59: 123–128. DOI: 10.1016/j.canep.2018.12.013
|
[11] |
PANKAJ S, NAZNEEN S, KUMARI S, et al. Comparison of conventional Pap smear and liquid-based cytology: A study of cervical cancer screening at a tertiary care center in Bihar. Indian J Cancer,2018,55(1): 80–83. DOI: 10.4103/ijc.IJC_352_17
|
[12] |
WANG M Z, FENG R M, WANG S, et al. Clinical performance of human papillomavirus testing and visual inspection with acetic acid in primary, combination, and sequential cervical cancer screening in China. Sex Transm Dis,2019,46(8): 540–547. DOI: 10.1097/OLQ.0000000000001026
|
[13] |
ZHENG B, AUSTIN R M, LIANG X, et al. PPV of an HSIL cervical cytology result in China's largest CAP-certified laboratory. J Am Soc Cytopathol,2015,4(2): 84–89. DOI: 10.1016/j.jasc.2014.10.005
|
[14] |
CHAN K K, LIU S S, WEI N, et al. Primary HPV testing with cytology versus cytology alone in cervical screening--A prospective randomized controlled trial with two rounds of screening in a Chinese population. Int J Cancer,2020,147(4): 1152–1162. DOI: 10.1002/ijc.32861
|
[15] |
宋波, 吴久玲, 宋莉, 等. 2012年我国农村妇女宫颈癌检查状况分析. 中国妇幼卫生杂志,2015,6(1): 1–4. DOI: 10.19757/j.cnki.issn1674-7763.2015.01.001
|
[16] |
COLDMAN A J, VAN NIEKERK D, KRAJDEN M, et al. Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per-protocol eligible for routine screening. Int J Cancer,2020,146(7): 1810–1818. DOI: 10.1002/ijc.32524
|
[17] |
WANG Z, WANG T, YANG J, et al. Diagnostic yield and performance of a large population-based cervical cancer screening program in high-risk rural China. J Cancer,2020,11(13): 4000–4006. DOI: 10.7150/jca.41472
|
[18] |
OGILVIE G S, KRAJDEN M, VAN NIEKERK D, et al. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. Int J Cancer,2017,140(2): 440–448. DOI: 10.1002/ijc.30454
|
[19] |
LIN C Q, ZENG X, CUI J F, et al. Stability study of cervical specimens collected by swab and stored dry followed by human papillomavirus DNA detection using the cobas 4800 test. J Clin Microbiol,2017,55(2): 568–573. DOI: 10.1128/JCM.02025-16
|
[20] |
OGILVIE G S, VAN NIEKERK D, KRAJDEN M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA,2018,320(1): 43–52. DOI: 10.1001/jama.2018.7464
|
[21] |
KOLIOPOULOS G, NYAGA V N, SANTESSO N, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev,2017,8(8): CD008587. DOI: 10.1002/14651858.CD008587.pub2
|
[22] |
TERMRUNGRUANGLERT W, KHEMAPECH N, TANTITAMIT T, et al. Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology. J Gynecol Oncol, 2019, 30(2): e17[2021-11-20]. https://doi.org/10.3802/jgo.2019.30.e17.
|
[23] |
ARBYN M, ANTTILA A, JORDAN J, et al. European guidelines for quality assurance in cervical cancer screening--Summary document. Ann Oncol,2010,21(3): 448–458. DOI: 10.1093/annonc/mdp471
|
[24] |
ZHANG S, MCNAMARA M, BATUR P. Cervical cancer screening: What's new? Updates for the busy clinician. Am J Med,2018,131(6): 702.e701–702.e705.
|
[25] |
HE L, HE J. Distribution of high-risk HPV types among women in Sichuan province, China: A cross-sectional study. BMC Infect Disv,2019,19(1): 390. DOI: 10.1186/s12879-018-3567-x
|
[26] |
ANDERSEN B, NJOR S H, JENSEN A M S, et al. HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older: A prospective study. Int J Gynecol Cancer,2020,30(11): 1678–1683. DOI: 10.1136/ijgc-2020-001457
|
[27] |
SUTEU O, BLAGA M L, NYGÅRD M, et al. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania. Eur J Cancer Prev,2020,29(2): 141–148. DOI: 10.1097/CEJ.0000000000000522
|
[28] |
CHEN X, XU H, XU W, et al. Prevalence and genotype distribution of human papillomavirus in 961, 029 screening tests in southeastern China (Zhejiang Province) between 2011 and 2015. Sci Rep,2017,7(1): 14813. DOI: 10.1038/s41598-016-0028-x
|
[29] |
ALTHOFF K N, PAUL P, BURKE A E, et al. Correlates of cervicovaginal human papillomavirus detection in perimenopausal women. J Womens Health (Larchmt),2009,18(9): 1341–1346. DOI: 10.1089/jwh.2008.1223
|
[30] |
MA L, WANG Y, GAO X, et al. Economic evaluation of cervical cancer screening strategies in urban China. Chin J Cancer Res,2019,31(6): 974–983. DOI: 10.21147/j.issn.1000-9604.2019.06.13
|